SOURCE: Bio-Rad Laboratories

November 13, 2006 08:00 ET

Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems

HERCULES, CA -- (MARKET WIRE) -- November 13, 2006 -- Bio-Rad Laboratories, Inc. (AMEX: BIO) (AMEX: BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has completed the purchase of Ciphergen Biosystems, Inc.'s ProteinChip Systems® business and worldwide technology rights to its Surface Enhanced Laser Desorption/Ionization (SELDI) for approximately $20 million in cash. The acquisition includes certain product lines, manufacturing capability, and intellectual property as well as access to Ciphergen's life science customer base. Under the terms of the agreement, Ciphergen will retain rights to the diagnostics market. Through a separate supply agreement, Bio-Rad will supply instruments and reagents to Ciphergen to support their diagnostics business. Bio-Rad also made a $3 million equity investment in Ciphergen as part of the transaction.

"With Ciphergen's ProteinChip Systems and SELDI technology, Bio-Rad is able to offer a more complete range of tools for proteomics workflows," said Norman Schwartz, Bio-Rad President and CEO. "Ciphergen products enable protein profiling and biomarker discovery and are a perfect complement to Bio-Rad's existing product line."

About SELDI Technology

The ProteinChip® SELDI System, which employs patented Surface Enhanced Laser Desorption/Ionization technology (SELDI), enables protein expression difference mapping, otherwise known as differential protein expression or expression proteomics. Proteomics research provides a direct approach to understanding the role of proteins in the biology of disease, monitoring disease progression and the therapeutic effects of drugs.

About Bio-Rad

Bio-Rad Laboratories, Inc. (AMEX: BIO) (AMEX: BIOb) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostics markets. The company is renowned worldwide among hospitals, universities, major research institutions as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs over 5,000 people globally and had revenues of $1.1 billion in 2005. For more information, please visit

Various statements made within this press release may constitute "forward-looking statements" for the purposes of the Securities and Exchange Commission's "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under the Securities Exchange Act of 1934. The forward-looking statements contained herein involve risks and uncertainties that could cause results to differ materially from the Company's expectation.

Contact Information

  • For more information, contact:
    Christine Tsingos
    Vice President and Chief Financial Officer

    Ron Hutton

    Bio-Rad Laboratories, Inc.
    Email Contact